poisar

Stocks · News reference

Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment

BenzingaChandrima Sanyal

XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    NSCLC Treatment Landscape Shifts as ESMO 2026 Spotlights MET, KRAS, and TROP2 Advances, Says DelveInsight

    The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.

  2. The Motley FoolDavid Dierking

    If You'd Invested $1,000 in an S&P 500 ETF Ahead of the Dot-Com Bubble, Here's What You'd Have Today

    A $1,000 investment in an S&P 500 ETF at the peak of the dot-com bubble in March 2000 would have grown to $8,050 by November 2026, representing a 705% total return and 8% average annual return despite 13 years of stagnation. The article demonstrates that long-term wealth building doesn't require perfect market timing, but rather consistent investment through market cycles.

  3. Zacks Investment ResearchNa

    Following Goldman Sachs & UBS? Bet on S&P 500 ETFs for 2027

    Goldman Sachs and UBS project the S&P 500 will rise to 8,700-8,900 by 2027, supported by strong economic growth, attractive valuations following recent market corrections, and continued earnings growth despite expected slowdown. The U.S. economy expanded 3.4% in Q3 2026, and consumer sentiment improved, suggesting robust spending ahead. However, concerns remain over AI regulation, elevated inflation, and potential Fed hawkishness.

  4. Globenewswire IncEisai Co., Ltd. And Biogen Inc.

    New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026

    Eisai and Biogen announced three-year real-world findings from the LEADER study of 560 patients showing LEQEMBI reduced progression to moderate/severe Alzheimer's disease by 76% compared to natural history controls. The analysis demonstrated 81% of patients remained stable or improved, 77% achieved amyloid-negative status, and subcutaneous maintenance therapy showed favorable safety profiles with no ARIA events reported.

  5. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.

  6. Zacks Investment ResearchNa

    Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

    The iShares U.S. Pharmaceuticals ETF (IHE) is reviewed as a reasonable option for investors seeking broad exposure to the Healthcare-Pharma sector. With $1.69 billion in assets and a 0.37% expense ratio, the fund has delivered strong year-to-date returns of 28.8% and one-year returns of 35.48%. However, it carries higher risk with a beta of 0.47 and standard deviation of 17.13%. Top holdings include Eli Lilly (26.88%), Johnson & Johnson, and Royalty Pharma, with the top 10 holdings representing 81.09% of assets.